ASH-话题@MedSci

#ASH#

242篇内容 | 2158人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1301238, encodeId=7dbe13012389d, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=AZ收购了Ionis的NASH候选药物, objectType=article, longId=134876, objectId=852e1348e68f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=852e1348e68f, replyNumber=0, likeNumber=68, createdTime=2018-04-12, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=852e1348e68f, moduleTitle=AZ收购了Ionis的NASH候选药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=852e1348e68f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301237, encodeId=ff95130123ebc, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=J Hepatol：饮食和化学药物诱导的疾病快速进展的NASH模型, objectType=article, longId=133957, objectId=84a113395e5f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84a113395e5f, replyNumber=0, likeNumber=60, createdTime=2018-04-02, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84a113395e5f, moduleTitle=J Hepatol：饮食和化学药物诱导的疾病快速进展的NASH模型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84a113395e5f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301236, encodeId=83d9130123687, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=PAPASH综合征一例, objectType=article, longId=132403, objectId=ecfe132403a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ecfe132403a4, replyNumber=0, likeNumber=64, createdTime=2018-03-16, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ecfe132403a4, moduleTitle=PAPASH综合征一例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ecfe132403a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301235, encodeId=c424130123598, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=Liver Int：Selonsertib治疗的肝纤维化2-3期的NASH患者，肝胶原蛋白的减少是PROs改善的最相关因素, objectType=article, longId=128982, objectId=d12f128982c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d12f128982c6, replyNumber=0, likeNumber=84, createdTime=2018-02-07, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d12f128982c6, moduleTitle=Liver Int：Selonsertib治疗的肝纤维化2-3期的NASH患者，肝胶原蛋白的减少是PROs改善的最相关因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d12f128982c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301234, encodeId=aeb413012347c, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=NIH专家建议用DASH饮食控制血压,比吃药好, objectType=article, longId=125774, objectId=4bd3125e7479, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4bd3125e7479, replyNumber=0, likeNumber=66, createdTime=2018-01-07, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4bd3125e7479, moduleTitle=NIH专家建议用DASH饮食控制血压,比吃药好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4bd3125e7479)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301233, encodeId=9c50130123374, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2017 ASH】Pollux研究的有效性和安全性分析更新:DRd对比Rd治疗RR-MM, objectType=article, longId=124424, objectId=eacf12442473, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eacf12442473, replyNumber=0, likeNumber=34, createdTime=2017-12-25, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eacf12442473, moduleTitle=【2017 ASH】Pollux研究的有效性和安全性分析更新:DRd对比Rd治疗RR-MM, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eacf12442473)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301232, encodeId=ad7e130123267, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=2017ASH美国血液学学术年会--梅斯报道专区, objectType=article, longId=122539, objectId=5378122539a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5378122539a4, replyNumber=0, likeNumber=24, createdTime=2017-12-19, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5378122539a4, moduleTitle=2017ASH美国血液学学术年会--梅斯报道专区, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5378122539a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301231, encodeId=e16013012316e, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=黄仲夏教授：ASH大会多发性骨髓瘤新药新检测概述, objectType=article, longId=123559, objectId=9b5e12355911, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b5e12355911, replyNumber=0, likeNumber=63, createdTime=2017-12-17, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b5e12355911, moduleTitle=黄仲夏教授：ASH大会多发性骨髓瘤新药新检测概述, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b5e12355911)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301230, encodeId=11c3130123042, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2017 ASH】2017美国血液学年会花絮（三）——互道珍重、相约明年！, objectType=article, longId=123313, objectId=c1ff1233137f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1ff1233137f, replyNumber=0, likeNumber=43, createdTime=2017-12-15, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1ff1233137f, moduleTitle=【2017 ASH】2017美国血液学年会花絮（三）——互道珍重、相约明年！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1ff1233137f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301229, encodeId=42f31301229c5, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2017 ASH】第59届美国血液学会年会闭幕演讲集锦, objectType=article, longId=123312, objectId=d8df12331219, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8df12331219, replyNumber=0, likeNumber=62, createdTime=2017-12-15, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8df12331219, moduleTitle=【2017 ASH】第59届美国血液学会年会闭幕演讲集锦, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8df12331219)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301228, encodeId=901e130122898, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2017 ASH】复发难治性慢性淋巴细胞白血病17p缺失突变患者治疗方案的选择——伊布替尼vs HSCT, objectType=article, longId=123311, objectId=ff8a12331154, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff8a12331154, replyNumber=0, likeNumber=23, createdTime=2017-12-15, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff8a12331154, moduleTitle=【2017 ASH】复发难治性慢性淋巴细胞白血病17p缺失突变患者治疗方案的选择——伊布替尼vs HSCT, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff8a12331154)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301227, encodeId=b7ee130122eb5, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2017 ASH】伊布替尼、卡非佐米以及地塞米松联合治疗对复发难治性多发性骨髓瘤II期临床效果显著, objectType=article, longId=123310, objectId=7e0a123310a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e0a123310a5, replyNumber=0, likeNumber=26, createdTime=2017-12-15, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e0a123310a5, moduleTitle=【2017 ASH】伊布替尼、卡非佐米以及地塞米松联合治疗对复发难治性多发性骨髓瘤II期临床效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e0a123310a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301226, encodeId=f593130122658, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2017 ASH】伊布替尼联合纳武单抗对多种复发性淋巴瘤有效, objectType=article, longId=123208, objectId=da9a1232083b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da9a1232083b, replyNumber=0, likeNumber=22, createdTime=2017-12-14, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da9a1232083b, moduleTitle=【2017 ASH】伊布替尼联合纳武单抗对多种复发性淋巴瘤有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da9a1232083b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301225, encodeId=68b71301225ef, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2017 ASH】Brentuximab Vedotin对CD30+皮肤T细胞淋巴瘤的治疗效果显著优于甲氨蝶呤或贝沙罗汀标准方案, objectType=article, longId=123207, objectId=4dfc12320e42, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4dfc12320e42, replyNumber=0, likeNumber=19, createdTime=2017-12-14, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4dfc12320e42, moduleTitle=【2017 ASH】Brentuximab Vedotin对CD30+皮肤T细胞淋巴瘤的治疗效果显著优于甲氨蝶呤或贝沙罗汀标准方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4dfc12320e42)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301224, encodeId=87df130122488, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2017 ASH】2017美国血液学年会花絮（二）——墙报区的学术交流, objectType=article, longId=123206, objectId=65fc123206a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65fc123206a5, replyNumber=0, likeNumber=26, createdTime=2017-12-14, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65fc123206a5, moduleTitle=【2017 ASH】2017美国血液学年会花絮（二）——墙报区的学术交流, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65fc123206a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301223, encodeId=e13b130122313, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2017 ASH】淋巴瘤分会场精彩研究报告集锦（二）, objectType=article, longId=123205, objectId=9c1712320567, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c1712320567, replyNumber=0, likeNumber=24, createdTime=2017-12-14, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c1712320567, moduleTitle=【2017 ASH】淋巴瘤分会场精彩研究报告集锦（二）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c1712320567)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301222, encodeId=c4a41301222b7, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2017 ASH】伊布替尼可有效控制老年慢性淋巴细胞白血病进展并改善患者生活质量, objectType=article, longId=123152, objectId=40001231522f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40001231522f, replyNumber=0, likeNumber=25, createdTime=2017-12-14, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40001231522f, moduleTitle=【2017 ASH】伊布替尼可有效控制老年慢性淋巴细胞白血病进展并改善患者生活质量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40001231522f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301221, encodeId=69971301221ba, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2017 ASH】RESONATE-2研究证实对于未经治疗的慢性淋巴细胞白血病患者，伊布替尼单药在延长无进展生存期和安全性方面均优于多种免疫化疗方案, objectType=article, longId=123151, objectId=925712315133, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=925712315133, replyNumber=0, likeNumber=22, createdTime=2017-12-14, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=925712315133, moduleTitle=【2017 ASH】RESONATE-2研究证实对于未经治疗的慢性淋巴细胞白血病患者，伊布替尼单药在延长无进展生存期和安全性方面均优于多种免疫化疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=925712315133)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301220, encodeId=eb8e13012201f, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2017 ASH】淋巴瘤分会场精彩研究报告集锦, objectType=article, longId=123150, objectId=3ca512315005, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ca512315005, replyNumber=0, likeNumber=22, createdTime=2017-12-14, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ca512315005, moduleTitle=【2017 ASH】淋巴瘤分会场精彩研究报告集锦, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ca512315005)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1301219, encodeId=dd2213012195b, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, objectTitle=【2017 ASH】2017美国血液学年会全新花絮——快来看看现场都有些什么？, objectType=article, longId=123149, objectId=9ccc123149ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ccc123149ba, replyNumber=0, likeNumber=23, createdTime=2017-12-14, rootId=0, userName=kksonne, userId=39a0295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ccc123149ba, moduleTitle=【2017 ASH】2017美国血液学年会全新花絮——快来看看现场都有些什么？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ccc123149ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ASH

2020-05-29

kksonne (审核中...)

前往app查看评论内容

#ASH#

AZ收购了Ionis的NASH候选药物

2018-04-12

kksonne (审核中...)

前往app查看评论内容

#ASH#

J Hepatol：饮食和化学药物诱导的疾病快速进展的NASH模型

2018-04-02

kksonne (审核中...)

前往app查看评论内容

#ASH#

PAPASH综合征一例

2018-03-16

kksonne (审核中...)

前往app查看评论内容

#ASH#

Liver Int：Selonsertib治疗的肝纤维化2-3期的NASH患者，肝胶原蛋白的减少是PROs改善的最相关因素

2018-02-07

kksonne (审核中...)

前往app查看评论内容

#ASH#

NIH专家建议用DASH饮食控制血压,比吃药好

2018-01-07

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2017 ASH】Pollux研究的有效性和安全性分析更新:DRd对比Rd治疗RR-MM

2017-12-25

kksonne (审核中...)

前往app查看评论内容

#ASH#

2017ASH美国血液学学术年会--梅斯报道专区

2017-12-19

kksonne (审核中...)

前往app查看评论内容

#ASH#

黄仲夏教授：ASH大会多发性骨髓瘤新药新检测概述

2017-12-17

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2017 ASH】2017美国血液学年会花絮（三）——互道珍重、相约明年！

2017-12-15

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2017 ASH】第59届美国血液学会年会闭幕演讲集锦

2017-12-15

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2017 ASH】复发难治性慢性淋巴细胞白血病17p缺失突变患者治疗方案的选择——伊布替尼vs HSCT

2017-12-15

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2017 ASH】伊布替尼、卡非佐米以及地塞米松联合治疗对复发难治性多发性骨髓瘤II期临床效果显著

2017-12-15

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2017 ASH】伊布替尼联合纳武单抗对多种复发性淋巴瘤有效

2017-12-14

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2017 ASH】Brentuximab Vedotin对CD30+皮肤T细胞淋巴瘤的治疗效果显著优于甲氨蝶呤或贝沙罗汀标准方案

2017-12-14

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2017 ASH】2017美国血液学年会花絮（二）——墙报区的学术交流

2017-12-14

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2017 ASH】淋巴瘤分会场精彩研究报告集锦（二）

2017-12-14

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2017 ASH】伊布替尼可有效控制老年慢性淋巴细胞白血病进展并改善患者生活质量

2017-12-14

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2017 ASH】RESONATE-2研究证实对于未经治疗的慢性淋巴细胞白血病患者，伊布替尼单药在延长无进展生存期和安全性方面均优于多种免疫化疗方案

2017-12-14

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2017 ASH】淋巴瘤分会场精彩研究报告集锦

2017-12-14

kksonne (审核中...)

前往app查看评论内容

#ASH#

【2017 ASH】2017美国血液学年会全新花絮——快来看看现场都有些什么？

2017-12-14

科室
- - 订阅+
  - 更多科室
工具
服务